Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Achondroplasia is described in the packet as the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia. It is also indexed under the abbreviation ACH and the names achondroplastic dwarfism, achondroplastic physique, and chondrodystrophia. According to expert review (GeneReviews), it is the most common form of inherited disproportionate short stature, with best estimates of 1 in 26,000 to 28,000 live births. The packet identifies FGFR3 as the associated gene, with definitive ClinGen validity, and lists autosomal dominant inheritance. The affected organ systems recorded are growth and respiratory.
According to expert review, individuals with achondroplasia have short stature with rhizomelic shortening of the limbs, macrocephaly, characteristic facies with frontal bossing and midface retrusion, exaggerated lumbar lordosis, limitation of elbow extension and rotation, genu varum, brachydactyly, and a trident appearance of the hands. Excess mobility of the knees, hips, and most other joints is described as common. The review gives average adult height as about 129.9 cm for men and 122.4 cm for women.
The packet's phenotype data list disproportionate short stature, limb undergrowth, bowing of the legs, kyphosis, and thoracolumbar kyphosis as very frequent (80-99%), and macrocephaly, frontal bossing, floppy infant presentation, trident hand, and limited elbow extension as frequent (30-79%). Several other terms in the packet's phenotype list carry an always-present label but are not described in the expert review, so they are not summarized here.
Other features described in the review include obesity, which is called a major problem and can manifest in early childhood, and macrocephaly in most children, with markedly delayed sutural closure. Hydrocephalus requiring treatment is reported in fewer than 5% of individuals. Some infants have a narrow craniocervical junction, which the review links to central apnea and, in some cases, to cervical myelopathy signs such as hyperreflexia and clonus. The review also describes restrictive pulmonary disease, obstructive sleep apnea, and lumbar stenosis in adults.
The packet lists FGFR3 as the associated gene, with a definitive ClinGen gene-disease validity classification, located on chromosome 4. According to expert review, achondroplasia arises through a gain-of-function mechanism, and an estimated 99% of affected individuals carry one of two common pathogenic variants. Inheritance is listed as autosomal dominant. The review reports that penetrance is 100%, meaning all individuals with a heterozygous FGFR3 pathogenic variant associated with achondroplasia show clinical manifestations, and that clinical manifestations vary modestly. Approximately 80% of individuals are reported to have the condition because of a de novo FGFR3 pathogenic variant, which is associated with advanced paternal age and is exclusively paternally inherited, while approximately 20% have at least one parent with achondroplasia. Presumed parental gonadal mosaicism has also been reported.
According to expert review, the diagnosis can be established solely on clinical and radiographic features. In newborns, suggestive clinical features listed are proximal shortening of the arms, a large head, a narrow chest, and short fingers with a trident configuration. Radiographic features that can establish the diagnosis include square ilia with horizontal acetabula, a narrow sacrosciatic notch, proximal femoral radiolucency, generalized metaphyseal abnormality including flaring, and decreasing interpedicular distance caudally. In older individuals, disproportionate short stature, macrocephaly with frontal bossing, midface retrusion, rhizomelic shortening of the arms, brachydactyly with trident hands, genu varum, thoracolumbar kyphosis, and exaggerated lumbar lordosis are listed, along with short robust tubular bones and narrowing of the caudal interpedicular distance on imaging.
The review states that individuals with typical clinical and radiographic features generally do not need molecular confirmation, and that absence of a known family history does not preclude the diagnosis. Where there is uncertainty, identification of a heterozygous pathogenic or likely pathogenic FGFR3 variant by molecular genetic testing can establish the diagnosis. Targeted analysis for the two common variants and multigene panels are described as testing approaches, and testing for intragenic deletions or duplications is described as unlikely to identify a disease-causing variant.
The packet lists vosoritide (Voxzogo), a C-type natriuretic peptide analog, as an FDA-approved treatment with active market status, approved through a new drug application reviewed by the FDA's Center for Drug Evaluation and Research on 2021-11-19. According to expert review, it is used to increase height in children with achondroplasia until growth plates close, and studies reported an average of 1.57 cm of additional growth per year, along with improved spinal sagittal balance, decreased leg bowing, and improved physical aspects of health-related quality of life after three years. The review notes that final adult height after treatment is still to be determined and describes injection site reactions and transient hypotension as the most common side effects.
The review describes health supervision outlined by the American Academy of Pediatrics Committee on Genetics, with specialized skeletal dysplasia clinics also existing. Evaluations described after diagnosis include growth documentation using achondroplasia-specific standards, brain imaging for ventricular size, neurologic and musculoskeletal examination, assessment of the craniocervical junction by neuroimaging and polysomnography, developmental assessment, evaluation for restrictive pulmonary disease and sleep apnea, and audiologic evaluation. Surgical options described include posterior fossa decompression or endoscopic third ventriculostomy in some individuals with hydrocephalus and suboccipital decompression for craniocervical junction compression. Several other agents carry orphan drug designations for achondroplasia in the packet, including infigratinib, and a designation is not an approval; one recombinant FGFR3 record is listed as withdrawn.
The packet does not include a dedicated prognosis source beyond the expert review's clinical description. According to that review, some infants with achondroplasia die in the first year of life from complications related to the craniocervical junction, with population-based studies suggesting an excess risk of death as high as 7.5% without assessment and intervention, and as little as 0.3% with comprehensive evaluation and selective neurosurgical intervention. The review also states that obesity can aggravate morbidity associated with lumbar stenosis and possibly contributes to early mortality from cardiovascular complications in adults. Hydrocephalus requiring treatment is reported in fewer than 5% of individuals.
The packet records numerous clinical trials for achondroplasia, with clinical-trial records on ClinicalTrials.gov. Examples in the packet include a recruiting phase 2 study of TYRA-300 in children (NCT06842355, sponsor Tyra Biosciences, 2025-03-04 to 2030-06-01), a recruiting phase 2 study comparing BMN 333 with vosoritide in children (NCT07441876, sponsor BioMarin Pharmaceutical, 2026-04-20 to 2029-09-01), a recruiting phase 2 study of infigratinib in children under 3 years (NCT07169279, sponsor QED Therapeutics, 2025-11-19 to 2032-03-01), and a recruiting phase 2 study of TransCon CNP in infants (NCT06079398, sponsor Ascendis Pharma, 2024-01-23 to 2028-12-01). The packet also lists recruiting natural history and observational studies, such as NCT02597881 (Johns Hopkins University). A study title does not establish efficacy of the intervention it names. The packet's publication summary classifies 214 publications, with reviews and meta-analyses the dominant type.
Data assembled from 10 of 12 sources · Last updated Nov 18, 2026, 8:42 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
21 trials found
AI-curated news mentioning achondroplasia
Updated Sep 2, 2026
A new study benchmarks statistical inference and explainable AI to predict craniospinal surgery in pediatric patients with achondroplasia. This research addresses the unique challenges posed by rare diseases, potentially improving surgical decision-making.
Biomarin has secured 18-20% royalties on net sales from Ascendis' achondroplasia drug Yuviwel through a non-exclusive licensing agreement for the active ingredient navepegritide. This deal highlights the financial potential of treatments for achondroplasia.
A new study published in PubMed provides real-world evidence on the effectiveness and safety of vosoritide in Latin American patients with achondroplasia. This research contributes to the understanding of treatment outcomes in diverse populations.
BioMarin's Phase 3 trial of Voxzogo for hypochondroplasia demonstrated efficacy significantly exceeding previous results for achondroplasia. This positive outcome follows earlier safety concerns and positions Voxzogo favorably in the rare skeletal disorder market.
A qualitative study explores the experiences and treatment perspectives of adolescents and young adults with achondroplasia, along with insights from their caregivers. This research highlights the unique challenges faced by this population and informs future treatment approaches.